Всероссийская GMP-конференция | Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 100 markets every day.

Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area.

In specialty medicines, Teva has the world-leading innovative treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions, as well as a broad portfolio of respiratory products.

Teva is leveraging its generics and specialty capabilities in order to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies.

Teva’s net revenues in 2016 were $21.9 billion. For more information, visit www.tevapharm.com.

Teva’s operations in Russia exemplify the company’s attentive and responsible approach to all of the 80 markets in which it has a presence. This approach is a key element of Teva’s mission of providing patients around the world with quality accessible medicines. Russia has been included in Teva’s list of investment priorities.

Teva began operating in Russia in 1995 and is today one of the largest pharmaceutical companies on the Russian market with a portfolio of more than 300 products. Over the last five years, the company’s turnover in Russia has grown more than ten times over. Teva’s Russia division currently employs some 1,300 people.

In October 2014, as part of its international investment strategy, Teva opened a pharmaceutical facility in Yaroslavl. The plant, which has the capacity to produce up to 2 billion tablets a year, will supply products to Russia and neighbouring countries.

In October 2017, Teva presented its new corporate brand and Barrier Free concept to consumers. The company believes that there should be no barriers between people and their health in terms of inconveniences, lack of understanding, difficulties or lack of information. This is why Teva is going beyond just producing medicines to help people care about health – both their own and that of their loved ones – throughout their lives. Russia was one of the first countries in which the new brand was rolled out.

At the same time as the new brand launch, a new version of www.teva.ru was rolled out to support the Barrier Free concept. The site is a unique digital space offering information and services. It serves as a personal assistant for people, ensuring access to useful information and convenient service tools for managing health.

Over its 20 years on the Russian market, Teva has served its main aim of ensuring the health, safety and high quality of life of patients in Russia.